Did marijuana’s medical benefits profile just take a big hit?

TMR-sativex1/9/15– Study results released yesterday by GW Pharmaceuticals and partner Otsuka Pharmaceutical, could wind up putting a gorilla on marijuana’s back right when its momentum was starting to build. The study was the first part of a three-study phase 3 trial looking at Sativex as a treatment for cancer pain. As noted by GW’s Pharmaceuticals’ press release, Sativex failed to meet its primary endpoint of delivering a statistically significant difference in cancer pain reduction relative to the placebo. Furthermore, the secondary endpoints also missed the mark. Not an encouraging trial in the least. Read